Home › Markets › Health Care › EIKN

Eikon Therapeutics Inc. (EIKN)

EIKN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$6.72
-7.44% on the day
Market cap
$364.0M
Small cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.

Profile

FieldValue
TickerEIKN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2026
SEC CIK0001861123
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-02-05
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-08-13
Latest current report8-K2026-08-14

Source: SEC EDGAR submissions feed, 65 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.6%
1 month-25.8%
3 months-29.2%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-56.7%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
SCTXScribe Therapeutics Inc.$19.12-7.50%$362.0M
KYTXKyverna Therapeutics Inc.$5.77-7.08%$356.8M
FENCFennec Pharmaceuticals Inc.$10.18-5.04%$356.6M
TRXBTRex Bio Inc.$13.60-3.06%$373.3M
EDITEditas Medicine Inc.$2.44-11.09%$375.5M
CCCCC4 Therapeutics Inc.$2.78-9.15%$342.0M
ZURAZura Bio Limited$4.23+5.75%$405.4M
TECXTectonic Therapeutic Inc.$21.31-4.65%$416.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier